SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced the Company has been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial with HE3286 for the treatment of metabolic disorders. The Company expects to initiate clinical trials with HE3286 in the current quarter. The Company also announced additional confirmatory preclinical data indicating that HE3286 improves glucose disposal in models of type 2 diabetes and that the compound is acting through a novel pathway that may offer benefits over existing insulin sensitizers. These data were presented late last week at the 2nd International Congress on “Prediabetes” and the Metabolic Syndrome, Barcelona, Spain, April 25-28, 2007.
